Jack Kaye

Insider Reports History

Entity
Individual
Location
C/O Keryx Biopharmaceuticals, 750 Lexington Avenue, New York, US
Signature
/s/ Christian Klemt, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jack Kaye:

Stock Role Class Num Shares Value Price $ Report Date Ownership
uniQure N.V. Director Ordinary Shares 14.6K $70.1K $4.81 Jun 19, 2024 Direct
DYADIC INTERNATIONAL INC Director Common Stock 33.6K $46.3K $1.38 Jan 3, 2024 Direct
DYADIC INTERNATIONAL INC Director Stock Option 67.5K Jan 2, 2024 Direct
uniQure N.V. Director Stock Option (Right to Buy) 15.8K Jun 19, 2024 Direct
DYADIC INTERNATIONAL INC Director Restricted Stock Unit 0 $1.38 Jan 3, 2024 Direct

Insider Reports Filed by Jack Kaye

Symbol Company Period Transactions Value $ Form Type Date Filed Role
QURE uniQure N.V. Jun 19, 2024 2 $0 4 Jun 21, 2024 Director
QURE uniQure N.V. Jun 13, 2024 1 -$11.4K 4 Jun 17, 2024 Director
DYAI DYADIC INTERNATIONAL INC Jan 2, 2024 4 $0 4 Jan 4, 2024 Director
QURE uniQure N.V. Dec 31, 2023 2 $0 5 Feb 6, 2024 Director
QURE uniQure N.V. Jun 13, 2023 3 -$43.2K 4 Jun 20, 2023 Director
QURE uniQure N.V. Feb 27, 2023 1 -$7.68K 4 Mar 1, 2023 Director
DYAI DYADIC INTERNATIONAL INC Jan 3, 2023 2 $0 4 Jan 5, 2023 Director
DYAI DYADIC INTERNATIONAL INC Dec 31, 2022 2 $0 5 Jan 5, 2023 Director
QURE uniQure N.V. Jun 15, 2022 2 $0 4 Jun 17, 2022 Director
DYAI DYADIC INTERNATIONAL INC Jun 10, 2022 1 $0 4 Jun 14, 2022 Director
QURE uniQure N.V. Feb 28, 2022 1 -$10.1K 4 Mar 2, 2022 Director
QURE uniQure N.V. Feb 24, 2022 2 $0 4 Feb 28, 2022 Director
DYAI DYADIC INTERNATIONAL INC Jan 3, 2022 1 $0 4 Jan 5, 2022 Director